A roadmap for CDMOs willing to enter the cell and gene therapy market

The Global Market for Cell & Gene Therapy Manufacturing Services is growing rapidly and expected to reach $15.77 billion by 2028. In 2023 alone, the FDA approved 7 new cell and gene therapies. Consequently, more and more CMOs and CDMOs are investing and entering the space. Some examples include, Fujifilm, Samsung Biologics, Thermofisher, Catalent, Charles River Laboratories, AGC Biologics, Recipharm, Andelyn Biosciences, Evotec, Avid Bioservices, Batavia Biosciences, CellPoint Bioservices, CHA Medical & Bio Group, Exothera, Forecyte Bio, Genezen, Matica Biotechnology, PackGene Biotech.

PE firms are also investing, such as GHO Capital, which invested in RoslinCT, to expand into the promising field of iPSC-based therapies.

 

“Maybe you don’t want to be the first, but certainly you don’t want to be the last…“

 

Importantly, No one size fits all; you need a tailored approach to navigate the complexity in an ever-changing biotech environment.

This is how we assisted a leading CDMO, with over $150 million in turnover, that had identified cell therapy as an area of expansion. Thanks to an in-depth analysis and our network of experts, we delivered insights that supported over $300 million in acquisitions, investments, and strategic partnerships.

This is what we did (4 weeks):

1. Executive Training: A detailed overview specifically designed for executives to explain both the unique dynamics of the sector and its distinct characteristics compared to other biologic treatments.
2. Data Collection: Gathering data on current market trends, size, growth projections, key players, and regulatory landscape in cell therapy.
3. Stakeholder Interviews and Surveys: Conducting interviews with industry experts, potential clients, and key stakeholders to gain insights into market needs and expectations.
4. Competitor Analysis: Examining the strategies, strengths, and weaknesses of existing CDMOs in cell therapy (large players and new entries)
5. Technology Assessment: Evaluating the latest technologies and innovations in cell therapy manufacturing and development and IP constraints
6. Cost Estimation for cell therapy manufacturing processes
7. Identify opportunities for entering the cell therapy space by acquisition
8. Screen opportunities for best fit with client (in collaboration with the client’s team)